Hi, my name is Sam Yates. I'm a hematology oncology fellow in adult medicine at the University of Chicago Medicine. I'm here at ASH in San Diego in 2023 to present our work where we're doing a current trial in progress looking at the importance of nutrition and a patient's body composition, specifically the amount of muscle that they have in their body to be able to improve their outcomes for patients with AML as they're undergoing therapy for a new diagnosis of AML. So our study is looking at older adults, so patients who are 60 and older who have a new diagnosis of acute myeloid leukemia. And what we're trying to do is see the importance of a patient's nutritional status when they're first diagnosed and see how that changes as they're undergoing their therapy for their acute myeloid leukemia. The trial opened in March of 2023 and we have so far enrolled 26 patients onto the trial and have had very minimal missing data. Only one patient has had missing data thus far. We hope to accrue all of our patients over a two-year period and then publish our results. And the goal would be that we find that malnutrition and low muscle mass, or sarcopenia, is important for patients' outcomes early on, especially in their therapy. And if we can show that, then we will work on interventional work, particularly exercise training with walking and resistance training and then nutritional supplementation to improve outcomes for patients with acute myeloid leukemia.
HealthTree • December 20, 2023